Short answer
OPKO HEALTH, INC. (OPK) filed an 8-K current report with the SEC on July 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 operating and financial highlights announced for quarter ended June 30, 2026.
OPKO HEALTH, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 operating and financial highlights announced for quarter ended June 30, 2026
- Management conference call scheduled for business update, results discussion, and financial guidance
- Detailed metrics and guidance available in Exhibit 99.1 press release
- Disclosure furnished under Item 2.02, limiting Section 18 Exchange Act liability unless specifically incorporated
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $163.5M, up from $156.8M, while net loss narrowed to $8.4M from $148.4M
- Pharmaceuticals revenue rose to $89.0M, driven by $29.4M from Nicoya shares and stronger product sales
- Diagnostics revenue fell to $74.5M after the Labcorp oncology-asset divestiture, partly offset by an $18.1M earnout
- Cash, equivalents, marketable securities and restricted cash totaled $314.4M; $94.7M remained for share repurchases
- Full-year 2026 revenue guidance: $560M–$585M, with R&D expense projected at $125M–$135M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OPKO HEALTH, INC. 8-K filings
Get the next OPK 8-K as it lands
Follow OPK for push alerts, or ask the research agent what this filing means.